DARE - Daré Bioscience, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.98000
-0.00050 (-0.05%)
As of 1:14PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.98050
Open1.00000
Bid0.98000 x 21500
Ask0.98980 x 800
Day's Range0.95050 - 1.00630
52 Week Range0.74000 - 3.59000
Volume32,168
Avg. Volume177,438
Market Cap11.194M
Beta (3Y Monthly)4.21
PE Ratio (TTM)N/A
EPS (TTM)-2.82500
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Daré Bioscience, Inc. to Present an Overview of Novel Intra-Vaginal Ring (IVR) Technologies at the Partnership Opportunities in Drug Delivery (PODD) Meeting Held in Boston, MA October 17th – 18th

    Daré Bioscience, Inc. (DARE), a clinical-stage, women’s health-focused biopharmaceutical company, today announced it will be presenting scientific and technical details on its innovative intra-vaginal ring (IVR) technologies at the Partnership Opportunities in Drug Delivery (PODD) meeting being held on the 17th and 18th of October in Boston, Massachusetts. Daré’s Chief Scientific Officer, David Friend, PhD, will deliver a presentation entitled “Optimizing Drug Delivery Through Novel Intra-Vaginal Ring (IVR) Technology” on Wednesday, October 17th as part of the Track 2B sessions.  “With eight potentially first-in-class women’s health products in development, we are committed to bring to market differentiated products designed to expand treatment options, improve outcomes, and facilitate convenience for women.

  • GlobeNewswire9 days ago

    Daré Bioscience, Inc. to Present at the 2018 BIO Investor Forum

    SAN DIEGO, Oct. 10, 2018 -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that Sabrina Martucci Johnson, President.

  • Zacks Small Cap Researchlast month

    DARE: Upcoming Milestones Inc FDA Feedback on Topical Sildenafil FSAD Program

    Daré (DARE) continues to not only move their various development programs forward, but also continues to add promising candidates to their high-potential women’s health-focused pipeline. Relative to the latter, DARE’s most recent pipeline addition, CatSper, a potential first-in-kind contraceptive for both men and women, was announced in mid-July.

  • GlobeNewswirelast month

    Greg Matz Joins Daré Bioscience Board of Directors

    Daré Bioscience, Inc. (DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of Greg Matz to its board of directors. “Greg brings a broad and diverse skill set that includes organizational development and strategic planning for a global medical device company,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.

  • GlobeNewswire2 months ago

    Daré Bioscience, Inc. to Present at the H.C. Wainwright 20th Annual Global Investment Conference

    Daré Bioscience, Inc. (DARE), a clinical-stage, women’s biopharmaceutical company, today announced that John Fair, Chief Business Officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference on Thursday, September 6, 2018 at 12:05 p.m. Eastern Time. The company’s mission is to identify, develop and bring to market a portfolio of novel, differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women in the areas of contraception, vaginal health, sexual health, and fertility.

  • GlobeNewswire3 months ago

    Daré Bioscience, Inc. to Present at the Canaccord Genuity 38th Annual Growth Conference

    Daré Bioscience, Inc. (DARE), a clinical-stage, women’s biopharmaceutical company, today announced that John Fair, Chief Business Officer, will present at the Canaccord Genuity 38th Annual Growth Conference on Thursday, August 9, 2018 at 1:00 p.m. Eastern Time. Mr. Fair will present a Daré overview and provide an update on the Company’s portfolio programs. Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive and sexual health.

  • ACCESSWIRE3 months ago

    Daré Bioscience, Growing Through Collaborations, Male Contraceptive, Analysts Target

    NEW YORK, NY / ACCESSWIRE / July 23, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Daré Bioscience (DARE), a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's reproductive health. Daré's lead product candidate, Ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies. On July 16th, the company announced that it has entered into an asset transfer agreement with Hydra Biosciences, Inc. for the transfer of all of Hydra's interest in certain intellectual property relating to Hydra's CatSper ion channel target portfolio.

  • ACCESSWIRE4 months ago

    Free Daily Technical Summary Reports on Dermira and Three Other Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 18, 2018/ If you want a free Stock Review on DERM sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Daré Bioscience Inc. (NASDAQ: DARE), Dermira Inc. (NASDAQ: DERM), Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA), and Egalet Corp. (NASDAQ: EGLT).

  • Zacks Small Cap Research4 months ago

    DARE: Initiating Coverage of DARE With $6.75/share Price Target

    DARE is a pre-revenue, clinical-stage company engaged in the development of novel therapeutic technologies targeting unmet needs in women’s health. In July 2017, DARE obtained worldwide rights (licensed from ADVA-Tec) to Ovaprene, the company’s lead development program. While certain features of vaginal rings (including effectiveness, reversibility and convenience of monthly use) score high in consumer surveys and studies, hormone-related side-effects (including risk of serious cardiovascular events) are an oft-cited drawback of currently available options, such as NuvaRing (etonogestrel/ethinyl estradiol).

  • Daré Bioscience Inc (NASDAQ:DARE): When Will It Breakeven?
    Simply Wall St.5 months ago

    Daré Bioscience Inc (NASDAQ:DARE): When Will It Breakeven?

    Daré Bioscience Inc’s (NASDAQ:DARE): Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women’s reproductive health products in the United States. The US$13.12M market-cap posted a lossRead More...

  • ACCESSWIRE6 months ago

    Today’s Research Reports on Stocks to Watch: Dare Bioscience and ACADIA

    NEW YORK, NY / ACCESSWIRE / April 26, 2018 / Dare Biosicence shares were exploding on Wednesday after the women's biopharma company announced that it had entered into an exclusive worldwide license agreement for Juniper Pharmaceutical's Intravaginal Ring technology platform. Shares of Arcadia didn't have as good a day as Dare yesterday as news of the FDA reviewing the company's controversial Parkinson's drug Nuplazid surfaced. Daré Bioscience, Inc. shares closed up 56.69% on Wednesday with around 29 million shares traded.

  • ACCESSWIRE6 months ago

    Blog Exposure - BiondVax Pharma Initiated NIH-Sponsored Phase-2 Clinical Trial of M-001 in the US

    Stock Monitor: Dare Bioscience Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free research report on BiondVax Pharma Ltd (NASDAQ: BVXV ) (''BiondVax''). ...

  • ACCESSWIRE7 months ago

    Dare Bioscience, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 2, 2018 / Dare Bioscience, Inc. (NASDAQ: DARE ) will be discussing their earnings results in their Q4 Earnings Call to be held on April 2, 2018 at 4:30 PM Eastern Time. ...